Molecularly defined, rare CD133+ cancer progenitor cells (CPCs) have been identified in a subset of gliomas and exhibit striking differences in response to treatment when compared to more differentiated tumor cells (33). This evidence concerns the gene PROM1 and central nervous system cancer.